Jane Street’s Madrigal Pharmaceuticals MDGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $103M | Buy |
191,541
+155,703
| +434% | +$79.8M | 0.01% | 923 |
|
|
2026
Q1 | $18.8M | Sell |
35,838
-57,276
| -62% | -$27.4M | ﹤0.01% | 1837 |
|
|
2025
Q4 | $54.2M | Sell |
93,114
-2,620
| -3% | -$1.34M | 0.01% | 887 |
|
|
2025
Q3 | $43.9M | Buy |
+95,734
| New | +$35.7M | 0.01% | 1035 |
|
|
2025
Q2 | – | Sell |
-51,890
| Closed | -$15.5M | – | 10388 |
|
|
2025
Q1 | $17.2M | Buy |
51,890
+44,071
| +564% | +$14.5M | ﹤0.01% | 1427 |
|
|
2024
Q4 | $2.41M | Sell |
7,819
-7,078
| -48% | -$1.99M | ﹤0.01% | 3787 |
|
|
2024
Q3 | $3.16M | Sell |
14,897
-21,307
| -59% | -$5.45M | ﹤0.01% | 3624 |
|
|
2024
Q2 | $10.1M | Buy |
36,204
+11,053
| +44% | +$2.63M | ﹤0.01% | 2035 |
|
|
2024
Q1 | $6.72M | Sell |
25,151
-191,667
| -88% | -$45.2M | ﹤0.01% | 2234 |
|
|
2023
Q4 | $50.2M | Buy |
216,818
+113,432
| +110% | +$19.8M | 0.01% | 674 |
|
|
2023
Q3 | $15.1M | Buy |
103,386
+63,163
| +157% | +$11.9M | ﹤0.01% | 1355 |
|
|
2023
Q2 | $9.29M | Sell |
40,223
-74,969
| -65% | -$20.3M | ﹤0.01% | 1983 |
|
|
2023
Q1 | $27.9M | Buy |
115,192
+71,112
| +161% | +$19.4M | 0.01% | 797 |
|
|
2022
Q4 | $12.8M | Buy |
+44,080
| New | +$4.31M | 0.01% | 1375 |
|
|
2022
Q3 | – | Sell |
-27,392
| Closed | -$1.9M | – | 10136 |
|
|
2022
Q2 | $1.96M | Buy |
27,392
+497
| +2% | +$36.5K | ﹤0.01% | 4202 |
|
|
2022
Q1 | $2.64M | Sell |
26,895
-9,145
| -25% | -$771K | ﹤0.01% | 4222 |
|
|
2021
Q4 | $3.05M | Buy |
+36,040
| New | +$2.96M | ﹤0.01% | 3651 |
|
|
2021
Q3 | – | Sell |
-11,427
| Closed | -$987K | – | 10407 |
|
|
2021
Q2 | $1.11M | Buy |
11,427
+119
| +1% | +$14.1K | ﹤0.01% | 5602 |
|
|
2021
Q1 | $1.32M | Buy |
11,308
+3,283
| +41% | +$383K | ﹤0.01% | 4890 |
|
|
2020
Q4 | $892K | Sell |
8,025
-1,838
| -19% | -$225K | ﹤0.01% | 4848 |
|
|
2020
Q3 | $1.17M | Sell |
9,863
-37,380
| -79% | -$4.06M | ﹤0.01% | 3834 |
|
|
2020
Q2 | $5.35M | Buy |
+47,243
| New | +$4.65M | ﹤0.01% | 1772 |
|
|
2019
Q4 | – | Sell |
-3,697
| Closed | -$359K | – | 5482 |
|
|
2019
Q3 | $319K | Buy |
3,697
+1,174
| +47% | +$110K | ﹤0.01% | 4105 |
|
|
2019
Q2 | $265K | Buy |
2,523
+183
| +8% | +$19.6K | ﹤0.01% | 4361 |
|
|
2019
Q1 | $293K | Buy |
2,340
+347
| +17% | +$43.1K | ﹤0.01% | 4276 |
|
|
2018
Q4 | $225K | Sell |
1,993
-498
| -20% | -$77.1K | ﹤0.01% | 4373 |
|
|
2018
Q3 | $533K | Buy |
2,491
+639
| +35% | +$160K | ﹤0.01% | 3543 |
|
|
2018
Q2 | $518K | Buy |
+1,852
| New | +$325K | ﹤0.01% | 3558 |
|
|
2015
Q1 | – | Sell |
-457
| Closed | -$42K | – | 3348 |
|
|
2014
Q4 | $42K | Sell |
457
-4,221
| -90% | -$436K | ﹤0.01% | 2390 |
|
|
2014
Q3 | $493K | Buy |
4,678
+3,170
| +210% | +$441K | 0.01% | 1459 |
|
|
2014
Q2 | $216K | Buy |
1,508
+729
| +94% | +$107K | ﹤0.01% | 2138 |
|
|
2014
Q1 | $117K | Sell |
779
-548
| -41% | -$108K | ﹤0.01% | 2488 |
|
|
2013
Q4 | $243K | Buy |
+1,327
| New | +$243K | ﹤0.01% | 1846 |
|
|
2013
Q3 | – | Sell |
-8,066
| Closed | -$1.41M | – | 2953 |
|
|
2013
Q2 | $1.41M | Buy |
+8,066
| New | +$2.1M | 0.02% | 645 |
|
Other funds holding MDGL
BBA
RI
JT
ACA
PC
Jane Street's MDGL Position: Q2 2026 in Review
Jane Street increased its Madrigal Pharmaceuticals (MDGL) stake by 434% in Q2 2026, buying an estimated $79.8M and bringing the position to 191,541 shares worth $103M. The position accounts for 0.01% of the portfolio, ranked #923.
Jane Street first reported a position in MDGL in Q2 2013 and has held it in 34 quarters since. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.
- Jane Street held 191,541 shares of Madrigal Pharmaceuticals worth $103M as of Q2 2026.
- Jane Street bought 155,703 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $79.8M.
- Madrigal Pharmaceuticals made up 0.01% of Jane Street's portfolio in Q2 2026, its #923 holding.
- Jane Street first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 34 quarters since.
- 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.
Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.